Clinical trials: Pollen Allergy
Rhinitis, Allergic, Seasonal, Hay Fever
Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)
The primary objective of this placebo-controlled EEC study is to determine the time to onset of action of ciclesonide, applied as a nasal spray (200 mg, once daily) in patients with SAR.
- Trial name
- NCT00659594
- Testing
- Ciclesonide
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Allergic Rhinitis
Efficacy and Safety of Specific Immunotherapy With CLUSTOID Grass Pollen
The objective of this study is to assess the efficacy and safety of cluster immunotherapy with highly polymerized allergen extracts.
- Trial name
- NCT01012531
- Testing
- Subcutaneous injections with highly polymerized allergen extract
- Where
- Germany
- Volunteers
- 121 people
- Sponsor
- Roxall Medizin
Grass Pollen Allergy
Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy
The study will evaluate the dose response of immunotherapy against grass pollen allergy using the recombinant grass pollen vaccine BM32.
- Trial name
- NCT01445002
- Testing
- BM32
- Where
- Austria
- Volunteers
- 79 people
- Sponsor
- Biomay AG
Allergic Rhinitis, Healthy Volunteer
DSP-3025 Study of Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season
Investigate safety/tolerability after a single dose intranasal administration of DSP-3025 comparator placebo to healthy male volunteers and seasonal allergic rhinitis male patients out of season.
- Trial name
- NCT00925678
- Testing
- DSP-3025
- Where
- Japan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma Co., Ltd.
Seasonal Allergic Rhinitis
A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis
Finding out how fast azelastine nasal spray works in subjects with hay fever.
- Trial name
- GEYSER (NCT00561717)
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Bayer
Rhinitis, Allergic, Seasonal, Hay Fever
Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)
The primary objective of this placebo-controlled EEU study is to determine the time to onset of action of ciclesonide, applied as a nasal spray (200 mg, once daily) in patients with SAR.
- Trial name
- NCT00659503
- Testing
- Ciclesonide
- Where
- Canada
- Volunteers
- 420 people
- Sponsor
- AstraZeneca
Seasonal Allergic Rhinitis, Asthma
Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma
The purpose of this study is to determine whether it is safe to administer Ragweed-SPIRE to subjects suffering from both ragweed allergy and asthma.
- Trial name
- NCT02061670
- Testing
- Ragweed-SPIRE
- Where
- 5 sites in Canada
- Volunteers
- 55 people
- Sponsor
- Circassia Limited
Seasonal Allergic Rhinitis
A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
This is a trial to evaluate the safety and efficacy of SHR-1819 injection in the treatment of patients with seasonal allergic rhinitis.
- Trial name
- NCT07091357
- Testing
- SHR-1819 Injection
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Seasonal Allergic Rhinitis
Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Treatment of Seasonal Allergic Rhinitis (Study P05106)(COMPLETED)
This study is designed to assess the effectiveness of mometasone furoate nasal spray (MFNS) once daily compared with placebo in subjects with seasonal allergic rhinitis (SAR) in reducing the total symptom score.
- Trial name
- NCT00468312
- Testing
- Mometasone furoate nasal spray
- Volunteers
- 429 people
- Sponsor
- Organon and Co
Type I Hypersensitivity
Different Doses of Tyrosine Adsorbed Tree Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Tree Pollen
Allergen-specific immunotherapy (SIT), the administration of gradually increasing quantities of an allergen extract to an allergic patient, is a curative approach which directly treats the underlying allergic disease.
- Trial name
- NCT00118612
- Testing
- Tree MATA MPL - Therapeutic Regimen, Tree MATA MPL - Intermediate dose, Tree MATA MPL - Low dose
- Where
- Canada
- Volunteers
- 68 people
- Sponsor
- Allergy Therapeutics
Rhinitis, Allergic, Seasonal, Seasonal Allergic Rhinitis
Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber
This study is in patients with seasonal allergic rhinitis(SAR)and will compare the effect versus placebo of repeat doses of intranasal GSK256066 using the Vienna Challenge Chamber.
- Trial name
- NCT00377728
- Testing
- GSK256066
- Where
- Austria
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Seasonal Allergic Rhinitis
A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis
The study is a multicenter, randomized, double-blind, placebo-controlled seamless and adaptive-designed phase IIb/III study encompassing a phase IIb and a phase III component.
- Trial name
- Pumecitinib (NCT06837233)
- Testing
- Pumecitinib Nasal Spray 0.3%, Pumecitinib Nasal Spray 0.6%, Pumecitinib nasal spray 0.6%(twice daily)
- Where
- 20 sites in China
- Volunteers
- 179 people
- Sponsor
- Prime Gene Therapeutics Co., Ltd.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis
The objective of the present study is to characterize the dose-response relationship of PURETHAL® Mites with a nasal provocation test in order to support the optimal dose in terms of clinical efficacy and safety.
- Trial name
- NCT01438463
- Testing
- PURETHAL Mites 6,667 AU/ml, PURETHAL Mites 20,000 AU/ml, PURETHAL Mites 50,000 AU/ml
- Where
- 35 sites in Austria, Belgium and 3 more
- Volunteers
- 290 people
- Sponsor
- HAL Allergy
Seasonal Allergic Rhinitis
This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)
The purpose of this study is to evaluate how well mometasone furoate nasal spray (MFNS) works to relieve SAR symptoms compared to Placebo when symptoms are induced in a chamber setting.
- Trial name
- NCT00491504
- Testing
- Mometasone Furoate Nasal Spray
- Volunteers
- 310 people
- Sponsor
- Organon and Co
Birch Pollen Allergy, Grass Pollen Allergy
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
About 20% of the general population are affected by an allergy - with an upward trend. Quite often, allergic people do not consider their disease as serious and suffer from subsequent complications, like allergic asthma, later in…
- Conditions
- Birch Pollen Allergy, Grass Pollen Allergy, House Dust Mite Allergy, Cat Allergy
- Trial name
- MADMAX (NCT04435678)
- Testing
- ALEX² test using the MAX 45k automated laboratory system
- Where
- 2 sites in Austria
- Volunteers
- 839 people
- Sponsor
- MacroArray Diagnostics GmbH
Allergic Rhinoconjunctivitis
Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense
Based on EMA (European Medicines Agency) new guidelines on the clinical development of products for immunotherapy for the treatment of allergic diseases the aim of this study is to establish a dose-response relationship for…
- Trial name
- NCT01567306
- Testing
- Allergovac Depot
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 151 people
- Sponsor
- Roxall Medicina España S.A
Seasonal Allergic Rhinitis
A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of…
- Trial name
- G104 (NCT03931993)
- Testing
- Grass MATA MPL
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allergy Therapeutics
Allergic Rhinitis
A Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in Adults
The purpose of this study is to evaluate the clinical effectiveness, safety and pharmacokinetics of JNJ-17166864 in patients with seasonal allergic rhinitis.
- Trial name
- NCT00604123
- Testing
- JNJ-17166864
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Rhinitis, Allergic, Seasonal
Onset of Action of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray Compared With Placebo in Seasonal Allergic Rhinitis (C93-184)
This study investigated the onset of symptom relief following initiation of treatment with mometasone furoate (MK-0887/SCH 032088) 200 mcg administered once daily compared with placebo for 14 days.
- Trial name
- NCT03861559
- Testing
- mometasone furoate nasal spray
- Volunteers
- 201 people
- Sponsor
- Organon and Co
Seasonal Allergic Rhinitis
Allergen Challenge Trial of IRL201104 in Seasonal Allergic Rhinitis
The purpose of this allergen challenge study is to assess the efficacy of IRL201104 compared with placebo in adult participants with seasonal allergic rhinitis.
- Trial name
- NCT05098522
- Testing
- IRL201104
- Where
- 2 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- Revolo Biotherapeutics